{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T03:43:38Z","timestamp":1789962218775,"version":"4.0.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:00:00Z","timestamp":1528416000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Psychiatry"],"published-print":{"date-parts":[[2018,12]]},"DOI":"10.1186\/s12888-018-1764-1","type":"journal-article","created":{"date-parts":[[2018,6,8]],"date-time":"2018-06-08T00:56:47Z","timestamp":1528419407000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["High-density lipoprotein-cholesterol and antipsychotic medication in overweight inpatients with schizophrenia: post-hoc analysis of a Japanese nationwide survey"],"prefix":"10.1186","volume":"18","author":[{"given":"Shin","family":"Ono","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuro","family":"Sugai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manabu","family":"Yamazaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazutaka","family":"Shimoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takao","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Ozeki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norio","family":"Yasui-Furukori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kurefu","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toyoaki","family":"Sagae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiyuki","family":"Someya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,8]]},"reference":[{"key":"1764_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1192\/bjp.173.1.11","volume":"173","author":"EC Harris","year":"1998","unstructured":"Harris EC, Barraclough B. Excess mortality of mental disorder. Br J Psychiatry. 1998;173:11\u201353.","journal-title":"Br J Psychiatry"},{"key":"1764_CR2","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1093\/oxfordjournals.schbul.a033504","volume":"26","author":"L Dixon","year":"2000","unstructured":"Dixon L, Weiden P, Delahanty J, Goldberg R, Postrado L, Lucksted A, et al. Prevalence and correlates of diabetes in national schizophrenia samples. Schizophr Bull. 2000;26:903\u201312.","journal-title":"Schizophr Bull"},{"key":"1764_CR3","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.schres.2005.07.014","volume":"80","author":"JP McEvoy","year":"2005","unstructured":"McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, et al. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANES III. Schizophr Res. 2005;80:19\u201332.","journal-title":"Schizophr Res"},{"key":"1764_CR4","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1111\/j.1600-0447.2008.01317.x","volume":"119","author":"JM Meyer","year":"2009","unstructured":"Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand. 2009;119:4\u201314.","journal-title":"Acta Psychiatr Scand"},{"key":"1764_CR5","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1097\/HJR.0b013e32832c8891","volume":"16","author":"DR Chirovsky","year":"2009","unstructured":"Chirovsky DR, Fedirko V, Cui Y, Sazonov V, Barter P. Prospective studies on the relationship between high-density lipoprotein cholesterol and cardiovascular risk: a systematic review. Eur J Cardiovasc Prev Rehabil. 2009;16:404\u201323.","journal-title":"Eur J Cardiovasc Prev Rehabil"},{"key":"1764_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/j.2051-5545.2009.tb00199.x","volume":"8","author":"M De Hert","year":"2009","unstructured":"De Hert M, Schreurs V, Vancampfort D, Van Winkel R. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry. 2009;8:15\u201322.","journal-title":"World Psychiatry"},{"key":"1764_CR7","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1056\/NEJMoa051688","volume":"353","author":"JA Lieberman","year":"2005","unstructured":"Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005;353:1209\u201323.","journal-title":"N Engl J Med"},{"key":"1764_CR8","doi-asserted-by":"publisher","first-page":"701","DOI":"10.2165\/00003495-200464070-00003","volume":"64","author":"K Melkersson","year":"2004","unstructured":"Melkersson K, Dahl ML. Adverse metabolic effects associated with atypical antipsychotics: literature review and clinical implications. Drugs. 2004;64:701\u201323.","journal-title":"Drugs"},{"key":"1764_CR9","first-page":"36","volume":"65","author":"JW Newcomer","year":"2004","unstructured":"Newcomer JW. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs. J Clin Psychiatry. 2004;65:36\u201346.","journal-title":"J Clin Psychiatry."},{"issue":"Suppl 1","key":"1764_CR10","first-page":"1","volume":"19","author":"JW Newcomer","year":"2005","unstructured":"Newcomer JW. Second-generation (atypical) antipsychotics and metabolic effects: a comprehensive literature review. CNS Drugs. 2005;19(Suppl 1):1\u201393.","journal-title":"CNS Drugs"},{"key":"1764_CR11","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1177\/070674370605100803","volume":"51","author":"JW Newcomer","year":"2006","unstructured":"Newcomer JW, Haupt DW. The metabolic effects of antipsychotic medications. Can J Psychiatr. 2006;51:480\u201391.","journal-title":"Can J Psychiatr"},{"key":"1764_CR12","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/j.schres.2010.07.012","volume":"123","author":"C Rummel-Kluge","year":"2010","unstructured":"Rummel-Kluge C, Komossa K, Schwarz S, Hunger H, Schmid F, Lobos CA, et al. Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. Schizophr Res. 2010;123:225\u201333.","journal-title":"Schizophr Res"},{"key":"1764_CR13","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.schres.2015.05.004","volume":"166","author":"A Enez Darcin","year":"2015","unstructured":"Enez Darcin A, Yalcin Cavus S, Dilbaz N, Kaya H, Dogan E. Metabolic syndrome in drug-na\u00efve and drug-free patients with schizophrenia and in their siblings. Schizophr Res. 2015;166:201\u20136.","journal-title":"Schizophr Res"},{"issue":"9","key":"1764_CR14","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1007\/BF02534017","volume":"15","author":"MJ Albrink","year":"1980","unstructured":"Albrink MJ, Krauss RM, Lindgrem FT, von der Groeben J, Pan S, Wood PD. Intercorrelations among plasma high density lipoprotein, obesity and triglycerides in a normal population. Lipids. 1980;15(9):668\u201376.","journal-title":"Lipids"},{"key":"1764_CR15","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1172\/JCI106896","volume":"51","author":"DE Wilson","year":"1972","unstructured":"Wilson DE, Lees RS. Metabolic relationships among the plasma lipoproteins. Reciprocal changes in the concentrations of very low and low density lipoproteins in man. J Clin Invest. 1972;51:1051\u20137.","journal-title":"J Clin Invest"},{"issue":"1","key":"1764_CR16","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1007\/s11695-010-0170-7","volume":"21","author":"L Shamai","year":"2011","unstructured":"Shamai L, Lurix E, Shen M, Novaro GM, Szomstein S, Rosenthal R, et al. Association of body mass index and lipid profiles: evaluation of a broad spectrum of body mass index patients including the morbidly obese. Obes Surg. 2011;21(1):42\u20137.","journal-title":"Obes Surg"},{"issue":"1","key":"1764_CR17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1161\/01.ATV.1.1.13","volume":"1","author":"NR Phillips","year":"1981","unstructured":"Phillips NR, Havel RJ, Kane JP. Levels and interrelationships of serum and lipoprotein cholesterol and triglycerides. Association with adiposity and the consumption of ethanol, tobacco, and beverages containing caffeine. Arteriosclerosis. 1981;1(1):13\u201324.","journal-title":"Arteriosclerosis"},{"issue":"4","key":"1764_CR18","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1007\/BF02533428","volume":"14","author":"PD Wood","year":"1979","unstructured":"Wood PD, Haskell WL. The effect of exercise on plasma high density lipoproteins. Lipids. 1979;14(4):417\u201327.","journal-title":"Lipids"},{"issue":"4","key":"1764_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1097\/00043798-199508000-00005","volume":"2","author":"HR Superko","year":"1995","unstructured":"Superko HR. Exercise and lipoprotein metabolism. J Cardiovasc Risk. 1995;2(4):310\u20135.","journal-title":"J Cardiovasc Risk"},{"key":"1764_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.schres.2016.01.016","volume":"171","author":"T Sugai","year":"2016","unstructured":"Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, et al. Difference in prevalence of metabolic syndrome between Japanese outpatients and inpatients with schizophrenia: a nationwide survey. Schizophr Res. 2016;171:68\u201373.","journal-title":"Schizophr Res"},{"key":"1764_CR21","volume-title":"OECD health statistics","author":"Organisation for Economic Cooperation and Development","year":"2017","unstructured":"Organisation for Economic Cooperation and Development. OECD health statistics 2017."},{"key":"1764_CR22","series-title":"Statistics and Information Department, Minister's Secretariat, Ministry of Health and Welfare, Tokyo","volume-title":"Summary of Static\/Dynamic Surveys of Medical Institutions and Hospital Report","author":"Ministry of Health and Welfare","year":"2010","unstructured":"Ministry of Health and Welfare. Summary of Static\/Dynamic Surveys of Medical Institutions and Hospital Report 2010. Statistics and Information Department, Minister's Secretariat, Ministry of Health and Welfare, Tokyo."},{"key":"1764_CR23","volume-title":"Diagnostic and Statistical Manual of Mental Disorders","author":"American Psychiatric Association","year":"2000","unstructured":"American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Press; 2000. Text Revision","edition":"4"},{"key":"1764_CR24","volume-title":"International statistical classification of diseases and related health problems 10th revision","author":"World Health Organization","year":"2004","unstructured":"World Health Organization. International statistical classification of diseases and related health problems 10th revision. 2004."},{"issue":"Suppl 4","key":"1764_CR25","first-page":"8","volume":"68","author":"JW Newcomer","year":"2007","unstructured":"Newcomer JW. Antipsychotic medications: metabolic and cardiovascular risk. J Clin Psychiatry. 2007;68(Suppl 4):8\u201313.","journal-title":"J Clin Psychiatry"},{"key":"1764_CR26","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s00213-006-0564-3","volume":"189","author":"WK Chrzanowski","year":"2006","unstructured":"Chrzanowski WK, Marcus RN, Torbeyns A, Nyilas M, McQuade RD. Effectiveness of long-term aripiprazole therapy in patients with acutely relapsing or chronic, stable schizophrenia: a 52-week, open-label comparison with olanzapine. Psychopharmacology. 2006;189:259\u201366.","journal-title":"Psychopharmacology"},{"key":"1764_CR27","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.schres.2008.09.028","volume":"107","author":"R Perez-Iglesias","year":"2009","unstructured":"Perez-Iglesias R, Mata I, Pelayo-Teran JM, Amado JA, Garcia-Unzueta MT, Berja A, et al. Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-na\u00efve population. Schizophr Res. 2009;107:115\u201321.","journal-title":"Schizophr Res"},{"key":"1764_CR28","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.biopsych.2008.07.033","volume":"65","author":"WW Fleischhacker","year":"2009","unstructured":"Fleischhacker WW, McQuade RD, Marcus RN, Archibald D, Swanink R, Carson WH. A double-blind, randomized comparative study of aripiprazole and olanzapine in patients with schizophrenia. Biol Psychiatry. 2009;65:510\u20137.","journal-title":"Biol Psychiatry"},{"key":"1764_CR29","doi-asserted-by":"publisher","first-page":"856","DOI":"10.4088\/JCP.v63n1002","volume":"63","author":"DA Wirshing","year":"2002","unstructured":"Wirshing DA, Boyd JA, Meng LR, Ballon JS, Marder SR, Wirshing WC. The effects of novel antipsychotics on glucose and lipid levels. J Clin Psychiatry. 2002;63:856\u201365.","journal-title":"J Clin Psychiatry"},{"key":"1764_CR30","doi-asserted-by":"publisher","first-page":"e22662","DOI":"10.1371\/journal.pone.0022662","volume":"6","author":"VL Albaugh","year":"2011","unstructured":"Albaugh VL, Singareddy R, Mauger D, Lynch CJ. A double blind, placebo-controlled, randomized crossover study of the acute metabolic effects of olanzapine in healthy volunteers. PLoS One. 2011;6:e22662.","journal-title":"PLoS One"},{"key":"1764_CR31","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/JCP.0b013e318166c4f7","volume":"28","author":"AB Birkenaes","year":"2008","unstructured":"Birkenaes AB, Birkeland KI, Engh JA, Faerden A, Jonsdottir H, Ringen PA, et al. Dyslipidemia independent of body mass in antipsychotic-treated patients under real-life conditions. J Clin Psychopharmacol. 2008;28:132\u20137.","journal-title":"J Clin Psychopharmacol"},{"key":"1764_CR32","doi-asserted-by":"publisher","first-page":"242","DOI":"10.4306\/pi.2015.12.2.242","volume":"12","author":"SH Kang","year":"2015","unstructured":"Kang SH, Lee JI. Metabolic disturbances independent of body mass in patients with schizophrenia taking atypical antipsychotics. Psychiatry Investig. 2015;12:242\u20138.","journal-title":"Psychiatry Investig"},{"issue":"1","key":"1764_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1111\/pcn.12082","volume":"68","author":"Y Suzuki","year":"2014","unstructured":"Suzuki Y, Sugai T, Fukui N, Watanabe J, Ono S, Tsuneyama N, et al. High prevalence of underweight and undernutrition in Japanese inpatients with schizophrenia. Psychiatry Clin Neurosci. 2014;68(1):78\u201382.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1764_CR34","doi-asserted-by":"publisher","first-page":"e0166429","DOI":"10.1371\/journal.pone.0166429","volume":"11","author":"T Sugai","year":"2016","unstructured":"Sugai T, Suzuki Y, Yamazaki M, Shimoda K, Mori T, Ozeki Y, et al. High prevalence of obesity, hypertension, hyperlipidemia, and diabetes mellitus in Japanese outpatients with schizophrenia: a nationwide survey. PLoS One. 2016;11:e0166429.","journal-title":"PLoS One"},{"key":"1764_CR35","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1007\/s40279-013-0110-5","volume":"44","author":"S Mann","year":"2014","unstructured":"Mann S, Beedie C, Jimenez A. Differential effects of aerobic exercise, resistance training and combined exercise modalities on cholesterol and the lipid profile: review, synthesis and recommendations. Sports Med. 2014;44:211\u201321.","journal-title":"Sports Med"},{"issue":"2","key":"1764_CR36","doi-asserted-by":"publisher","first-page":"171","DOI":"10.2190\/PM.44.2.h","volume":"44","author":"Y Inamura","year":"2012","unstructured":"Inamura Y, Sagae T, Nakamachi K, Murayama N. Body mass index of inpatients with schizophrenia in Japan. Int J Psychiatry Med. 2012;44(2):171\u201381.","journal-title":"Int J Psychiatry Med"},{"issue":"5","key":"1764_CR37","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1002\/hup.2257","volume":"27","author":"F Centorrino","year":"2012","unstructured":"Centorrino F, Masters GA, Talamo A, Baldessarini RJ, \u00d6ng\u00fcr D. Metabolic syndrome in psychiatrically hospitalized patients treated with antipsychotics and other psychotropics. Hum Psychopharmacol. 2012;27(5):521\u20136.","journal-title":"Hum Psychopharmacol"},{"issue":"7","key":"1764_CR38","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.4088\/JCP.08r04392","volume":"70","author":"V Simon","year":"2009","unstructured":"Simon V, van Winkel R, De Hert M. Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. J Clin Psychiatry. 2009;70(7):1041\u201350.","journal-title":"J Clin Psychiatry"}],"container-title":["BMC Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12888-018-1764-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12888-018-1764-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T23:08:50Z","timestamp":1559948930000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpsychiatry.biomedcentral.com\/articles\/10.1186\/s12888-018-1764-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,8]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,12]]}},"alternative-id":["1764"],"URL":"https:\/\/doi.org\/10.1186\/s12888-018-1764-1","relation":{},"ISSN":["1471-244X"],"issn-type":[{"value":"1471-244X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,8]]},"assertion":[{"value":"20 December 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 May 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"All participants provided written consent prior to all study procedures. This research was approved by the Ethics Committee of the Japan Psychiatric Hospitals Association, Tokyo, Japan, and conforms to the provisions of the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Toshiyuki Someya has received research support or honoraria from Asahi Kasei Pharma Corp., Astellas Pharma Inc., Daiichi Sankyo Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co. Ltd., Mitsubishi Tanabe Pharma Co. Ltd., Mochida Pharmaceutical Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co. Ltd., Tsumura & Co., and Yoshitomi Pharmaceutical Industries. Yutaro Suzuki has received research support or honoraria from Janssen Pharmaceutical K.K., Mitsubishi Tanabe Pharma Co. Ltd., and Otsuka Pharmaceutical Co. Ltd. Kazutaka Shimoda has received research support or honoraria from Daiichi Sankyo Co. Ltd., Dainippon Sumitomo Pharma Co. Ltd., Eisai Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Meiji Seika Pharma Co. Ltd., Novartis Pharma K.K., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Shionogi & Co. Ltd., Takeda Pharmaceutical Co. Ltd., Tsumura & Co., Yoshitomi Pharmaceutical Industries Ltd., Asahi Kasei Pharma Corporation, Astellas Pharma Inc., Janssen Pharmaceutical K.K., Kowa Pharmaceutical Co. Ltd., Meiji Seika Pharma Co., Mitsubishi Tanabe Pharma Corporation Ltd., MSD K.K., Novartis Pharma K.K., and Ono Pharmaceutical Co. Ltd. Norio Yasui-Furukori has received research support or honoraria from Astellas Pharma Inc., Dainippon Sumitomo Pharma Co. Ltd., Eli Lilly Japan K.K., GlaxoSmithKline K.K., Janssen Pharmaceutical K.K., Meiji Seika Pharma Co., Mochida Pharmaceutical Co. Ltd., MSD K.K., Otsuka Pharmaceutical Co. Ltd., Pfizer Japan Inc., Takeda Pharmaceutical Co. Ltd., and Yoshitomi Pharmaceutical Industries. Norio Sugawara has received grant or research support from a Grant-in-Aid for Young Scientists (B), Ministry of Education, Culture, Sports, Science and Technology, Japan Grant B., a Karoji Memorial Fund for Medical Research Grant, and The Senshin Medical Research Foundation. Shin Ono has received grant or research support from the Hospitals Bureau Niigata Prefecture Government and a Grant-in-Aid for Scientific Research (C). There are no patents, products in development, or marketed products to declare. The other authors declare no potential conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s Note"}}],"article-number":"180"}}